

PULMONARY DRUG DELIVERY SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS



HLC094B
May 2014

Usha Nagavarapu
Project Analyst

ISBN: 1-56965-816-1



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE AND FORMAT	2
INTENDED AUDIENCE	3
METHODOLOGY	3
RELATED BCC RESEARCH REPORTS	3
ANALYST'S CREDENTIALS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, 2011-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	10
CURRENT MARKET TRENDS	10
TECHNOLOGY	10
<i>TABLE 1 COMMONLY USED INHALED DRUGS</i>	11
DRUG DELIVERY IN THE MODERN WORLD	11
INHALATION AS A TECHNIQUE	11
PULMONARY DRUG DELIVERY	12
<i>TABLE 2 KEY FACTS</i>	13
CONTRAINDICATIONS	13
<i>TABLE 3 ADVANTAGES AND DISADVANTAGES OF MDIS</i>	13
<i>TABLE 4 ALTERNATIVE TO CFC MDIS</i>	14
<i>TABLE 5 MDIS PHASE-OUT DATES: UNITED STATES</i>	14
DRY POWDER INHALERS	15
<i>TABLE 6 COMMON DPI DEVICES</i>	15
<i>TABLE 7 DPI: ADVANTAGES AND DISADVANTAGES</i>	16
Twisthaler	16
ACCESSORY DEVICES	16
NEBULIZERS	17
<i>TABLE 8 ADVANTAGES AND DISADVANTAGES OF NEBULIZERS</i>	17
PULMONARY CONDITIONS AND THERAPIES	17
RESPIRATORY SYSTEM	18
Lung	19
Role of Particle Size	20
SYSTEMIC AND LOCAL THERAPY	21
PULMONARY DRUG DELIVERY DEVICES	21
Device Characteristics	22
PULMONARY DRUG DELIVERY-THE FUTURE	26
INHALER DEVICES	27
<i>TABLE 9 INHALER DEVICES AND CHARACTERISTICS</i>	27

TOPIC	PAGE NO.
<i>TABLE 10 DOSAGE FORMS—INHALERS</i>	27
Available Products	28
<i>TABLE 11 METERED DOSE INHALERS</i>	28
<i>TABLE 12 DRY POWDER INHALERS</i>	29
COMMONLY USED INHALERS	29
<i>TABLE 13 COMMON COPD INHALERS</i>	29
INHALER-DRUG PROFILES	30
Aerosol Aztreonam (Cayston)	30
Dulera (Mometasone Furoate/Formoterol Fumarate Dihydrate)	31
Amikacin	32
Phase III INHALE Study Program	33
SYSTEMIC PULMONARY DELIVERY	33
Development of Exubera	34
Aerogen and Dance Pharmaceuticals	35
Safety Concerns	35
Future	35
Insulin-Exubera	36
MannKind's-Afrezza	36
Clinical Results	37
Study 171	37
Summary	37
Key Players	38
Pulmonary Drug Delivery-In a New Light	38
ASTHMA AND COPD-MAJOR RESPIRATORY DISEASE CONDITIONS	38
Asthma: Primary Respiratory Syndrome	38
Asthma and Obesity	40
<i>TABLE 14 ASTHMA AND BIOMARKERS</i>	41
Monitoring of Asthma	41
<i>TABLE 15 INHALED STEROIDS (ASTHMA INHALERS)</i>	42
<i>TABLE 16 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT</i>	43
Delivery Methods	43
Chronic Obstructive Pulmonary Disease (COPD)	45
What is COPD?	46
COPD and Causative Factors	46
<i>TABLE 17 COPD AND LUNG DAMAGE</i>	48
Diagnosis of COPD	49
COPD and Treatment	50
METHODS OF DRUG DELIVERY	51
<i>TABLE 18 COMMON COPD INHALERS ON THE MARKET</i>	52
Aerosols	52
<i>TABLE 19 COPD DRUGS ON THE MARKET</i>	53
Formulations	53
INHALATION MARKET	54
Asthma Prevalence and Statistics	54
COPD and Incidence	55
Disease and Epidemiology	56
<i>TABLE 20 INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR INHALED DRUGS, 2010 (% MARKET SHARE)</i>	56

TOPIC	PAGE NO.
CHAPTER 4 PULMONARY DRUG DELIVERY SYSTEM	59
BENEFITS OF PULMONARY DRUG DELIVERY SYSTEMS	59
INHALER DEVICES	59
<i>TABLE 21 INHALER DEVICES</i>	60
PULMONARY DRUG DELIVERY TECHNOLOGIES	60
Technology Descriptions	60
Wide Array of Applications	60
<i>TABLE 22 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION</i>	61
INHALERS	61
Metered-dose Inhalers	61
MDIs-How Does It Work?	62
History	62
MDIs and Drug Delivery	63
Advantages and Challenges for MDIs	63
MDIs and Corticosteroids	63
<i>TABLE 23 BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS)</i>	64
Bronchodilators	64
<i>TABLE 24 BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS)</i>	64
Combination Inhalers	65
Nonsteroidal Inhalers	65
Problems with MDI Use and Spacers	65
Propellants and MDI Development	67
Montreal Protocol	67
Millions Use Inhalers for Asthma or COPD	67
<i>TABLE 25 LIST OF INHALERS FOR ASTHMA AND COPD WITHOUT CFCs</i>	68
<i>TABLE 26 LIST OF METERED DOSE INHALERS AND INGREDIENTS</i>	69
Fluticasone	69
Fluticasone and Salmeterol	70
Flunisolide	70
Beclomethasone	70
TRANSITION TO HFA PROPELLANTS	70
Chlorofluorocarbons (CFCs)	70
<i>TABLE 27 THE SEVEN CFC INHALERS</i>	71
Analgesic Inhalers	71
DRY POWDER INHALER (DPI)	72
<i>TABLE 28 TYPES OF DPI DEVICES</i>	74
Types of DPI Devices	74
<i>TABLE 29 DPIS CURRENTLY ON THE MARKET</i>	74
<i>TABLE 30 TYPES OF DRY POWDER INHALERS (DPI)</i>	76
DPIs for Children	76
Nebulizers	77
How Do They Work?	78
Use	78
<i>TABLE 31 Nebulizers and Drugs</i>	78
<i>TABLE 32 NEBULIZERS: ADVANTAGES AND DISADVANTAGES</i>	80
Ultrasonic Nebulizers	80

TOPIC	PAGE NO.
<i>TABLE 33 VIBRATING MESH NEBULIZERS</i>	81
Small Volume Nebulizers: Electronic Vibrating Mesh (VM) Nebulizer	82
Factors Influencing Clinical Effectiveness of Inhalation Devices	82
CONCLUSIONS	83
CHAPTER 5 PULMONARY DRUG DELIVERY: DRUGS IN USE	85
CURRENT INHALATION DRUGS AND MARKET	85
AEROSOL AZTREONAM (CAYSTON)	85
DULERA (MOMETASONE FUROATE/FORMOTEROL FUMARATE DIHYDRATE)	86
PULMONARY DELIVERY OF SYSTEMIC DRUGS	87
Antibiotics	87
Analgesics	87
Anti-emetics	87
<i>TABLE 34 THERAPEUTIC AGENTS ADMINISTERED BY INHALATION</i>	87
Pulmonary Specific Vasodilators	88
Nicotine	88
Nebulizers for Pediatric Care	88
Vaccines	88
Obesity	89
Drugs and Inhalers: How Do They Work?	89
<i>TABLE 35 SHORT-ACTING BRONCHODILATOR INHALERS</i>	89
<i>TABLE 36 LONG-ACTING BRONCHODILATOR INHALERS</i>	90
Steroid Inhalers	90
<i>TABLE 37 INHALED STEROID MEDICATIONS</i>	90
<i>TABLE 38 COMBINATION INHALERS</i>	91
Breath-Activated Inhalers	91
Nebulizers	92
Pulmonary Delivery	92
Controlled Release	92
Formulations	95
Lactose Carrier Systems	95
Liposomes	95
PulmoSpheres	97
Biodegradable Polymers	98
CHAPTER 6 GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES	101
RESPIRATORY DISEASES	101
ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET	102
<i>TABLE 39 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 (\$ MILLIONS)</i>	102
<i>FIGURE 1 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 (\$ MILLIONS)</i>	103
GLOBAL RESPIRATORY DEVICES MARKET	103
COPD	104
DRUG DELIVERY MARKET	104
Drug Delivery Technologies and Market	104

TOPIC	PAGE NO.
European Drug Delivery Market	105
GLOBAL PHARMACEUTICAL MARKET	106
<i>TABLE 40 GLOBAL PHARMACEUTICAL SALES AND FORECAST, THROUGH 2018 (\$ BILLIONS)</i>	106
<i>FIGURE 2 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 (\$ BILLIONS)</i>	106
Pharmaceutical Growth Rates	107
Emerging Markets	107
<i>TABLE 41 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY REGION, THROUGH 2017 (\$ BILLIONS)</i>	108
A Shift to Generics as Patents Expire	108
Growth in New Drugs	108
United States Pharmaceutical Industry	109
Top 20 Pharmaceutical Companies	110
<i>TABLE 42 TOP 20 PHARMACEUTICAL COMPANIES, 2012 (\$ MILLIONS)</i>	110
<i>TABLE 43 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 (\$ MILLIONS)</i>	111
DRUG DELIVERY	111
DRUG DELIVERY MARKET	112
Global Market	113
<i>TABLE 44 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET</i>	114
<i>TABLE 45 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)</i>	114
<i>FIGURE 3 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)</i>	115
<i>TABLE 46 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)</i>	116
<i>FIGURE 4 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)</i>	116
Oral Drug Delivery	116
<i>TABLE 47 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)</i>	117
<i>FIGURE 5 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 (\$ MILLIONS)</i>	117
Implantable and Injectable Drug Delivery	118
<i>TABLE 48 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	118
<i>FIGURE 6 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018 (\$ MILLIONS)</i>	118
Transdermal Drug Delivery	119
<i>TABLE 49 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)</i>	120
<i>FIGURE 7 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)</i>	120
Drug Delivery Market in the U.S.	120
<i>TABLE 50 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	121
<i>FIGURE 8 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)</i>	121
PULMONARY DRUG DELIVERY	122
<i>TABLE 51 TOP ASTHMA AND COPD DRUGS</i>	122

TOPIC	PAGE NO.
<i>TABLE 52 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)</i>	122
<i>FIGURE 9 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)</i>	122
<i>TABLE 53 LEADING PULMONARY DRUG DELIVERY PLAYERS</i>	123
<i>TABLE 54 PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, THROUGH 2018 (\$ MILLIONS)</i>	124
<i>FIGURE 10 PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, 2011-2018 (\$ MILLIONS)</i>	124
ASTHMA AND COPD MARKET	125
<i>TABLE 55 WORLDWIDE MARKET FOR TOP INHALED DRUGS: SALES AND FORECAST 2012-2013 (\$ MILLIONS)</i>	126
<i>TABLE 56 UNITED STATES: TOP ASTHMA DRUGS SALES, 2012 AND 2013 (\$ MILLIONS)</i>	127
WHY PULMONARY DRUG DELIVERY?	127
Metered Dose Inhalers (MDIs)	128
<i>TABLE 57 MARKET FOR MDI TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)</i>	129
<i>FIGURE 11 MARKET FOR MDI TECHNOLOGIES, 2011-2018 (\$ MILLIONS)</i>	129
DRY POWDER INHALATION (DPI)	129
<i>TABLE 58 DPI DEVICES</i>	130
<i>TABLE 59 MARKET FOR DPI TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)</i>	131
<i>FIGURE 12 MARKET FOR DPI TECHNOLOGIES, 2011-2018 (\$ MILLIONS)</i>	131
Inhalers: Global Cost Comparison	132
GENERICS	133
Phase-out of CFC Inhalers and Historical Perspectives	133
CURRENT MARKET DYNAMICS	136
Rescue Inhalers	136
<i>TABLE 60 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%)</i>	136
Combination Inhalers	137
<i>TABLE 61 UNITED STATES: TOP ASTHMA DRUGS PRESCRIPTIONS, 2012 (\$ MILLIONS)</i>	137
Product Descriptions	137
Symbicort	137
ProAir and Qvar	137
Dulera	138
Spiriva	138
Advair	138
New Products	139
Breo Ellipta	139
Anoro Ellipta	139
Other Respiratory Development Programs	140
<i>TABLE 62 NEW PRODUCTS IN THE RESPIRATORY DRUG MARKET, 2013</i>	141
Ultibro Breezhaler	141
Impact on Advair Market in United States and Healthcare Changes	142
<i>TABLE 63 ADVAIR SALES AND FORECAST, 2011-2015 (\$ MILLIONS)</i>	142
<i>TABLE 64 GLAXOSMITHKLINE: RESPIRATORY DRUGS PHARMACEUTICALS—THREE MONTHS ENDED JUNE 30, 2013 (\$ MILLIONS)</i>	143
Arcapta Neohaler/Onbrez Breezhaler	143
Seebri Breezhaler	143

TOPIC	PAGE NO.
Theophylline	144
Flutiform	144
<i>TABLE 65 SKYEPHARMA: PRODUCTS</i>	144
<i>TABLE 66 PARTNER NETWORK</i>	145
Fluticasone/Salmeterol	145
<i>TABLE 67 TOP SELLING INHALERS, 2010 (\$ MILLIONS)</i>	147
Tiotropium Bromide	147
Other Drugs	149
MAJOR PLAYERS	149
GlaxoSmithKline	149
<i>TABLE 68 TOP SELLING DRUGS, 2010 (\$ MILLIONS/+/- %)</i>	149
CONCLUSION	150
Dry Powder Inhalation: A Promising Technology	150
<i>TABLE 69 GROWTH AREAS FOR INHALERS</i>	150
Generics for Advair: Teva	150
Nebulizers: Displaying Promising Growth	151
<i>TABLE 70 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2018 (\$ MILLIONS)</i>	151
<i>FIGURE 13 GLOBAL RESPIRATORY DEVICE MARKET, 2011-2018 (\$ MILLIONS)</i>	151
<i>TABLE 71 U.S. RESPIRATORY DEVICE MARKET, THROUGH 2018 (\$ MILLIONS)</i>	152
<i>FIGURE 14 U.S. RESPIRATORY DEVICES MARKET, 2011-2018 (\$ MILLIONS)</i>	153
<i>TABLE 72 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2018 (\$ MILLIONS)</i>	153
<i>FIGURE 15 GLOBAL MARKET FOR NEBULIZERS, 2011-2018 (\$ MILLIONS)</i>	154
Nebulizers on the Market	154
CHAPTER 7 GLOBAL MARKET TRENDS	157
GLOBAL TRENDS AND INHALER MARKET	157
ASIA	157
China	157
India	158
Iran	158
Regulatory Changes—Pulmonary Drug Delivery Hurdles	159
Increased Research and Development Efforts	159
Aerosol Delivery Market	159
Distribution Channels	160
GROWTH AND NEW DEVELOPMENTS	160
Pulmonary Disease Drug Market	161
Market Trends in Asia	161
Challenges and Future Development	162
Market Segmentation	162
Patient Involvement	163
Pulmonary Insulin	163
Exubera	164
Afrezza	164
INHALED SMALL MOLECULE THERAPEUTICS	165
<i>TABLE 37 INHALED STEROID MEDICATIONS</i>	165
SELECTED PROFILES OF DRUGS ON THE MARKET	166
Dulera	166

TOPIC	PAGE NO.
Arcapta (Indacaterol Maleate Inhalation Powder)	167
Daliresp	169
CHAPTER 8 KEY COMPANIES	171
KEY COMPANIES	171
KEY DEVELOPMENTS	171
SOME KEY COMPANIES AND DESCRIPTIONS	172
3M	172
ADAMIS PHARMACEUTICALS CORP.	172
AKELA PHARMA INC (CANADA)	173
ALEXZA PHARMACEUTICALS	173
ALKERMES	174
ALPHARX INC.	174
AOP ORPHAN PHARMACEUTICALS	175
APT PHARMACEUTICALS INC.	175
APTAR PHARMA	175
ARADIGM CORP. (USA)	176
ASTRAZENECA PLC (U.K.)	176
AVANIR PHARMACEUTICALS	177
AXENTIS PHARMA	177
BOEHRINGER INGELHEIM	177
<i>TABLE 74 COPD PRODUCTS</i>	178
CIPLA	178
<i>TABLE 75 RANGE OF DRY POWDER INHALER DEVICES</i>	179
CONSORT MEDICAL PLC (UK)	179
DAIICHI SANKYO	180
DEY L.P. (USA)	180
GILEAD SCIENCES	180
GLAXOSMITHKLINE PLC (UK)	181
GRACEWAY PHARMACEUTICALS, LLC (USA)	181
HOVIONE	181
INSPIRE PHARMACEUTICALS INC.	182
MANNKIND	182
MAP PHARMACEUTICALS	183
MERCK & CO.	183
MICRODOSE THERAPEUTX	184
MPEX PHARMACEUTICALS	184
NEKTAR THERAPEUTICS	184
NEXT SAFETY	185
NOVARTIS INTERNATIONAL AG	185
OPTINOSE	186
ORIEL THERAPEUTICS INC.	186
PEARL THERAPEUTICS	186
PFIZER	187
PHARMAXIS	187
PULMATRIX	188
RESPIRICS	188

TOPIC	PAGE NO.
SAVARA	188
SKYEPHARMA PLC (UK)	189
SUNOVION PHARMACEUTICALS INC.	189
SYNAIRGEN RESEARCH LTD	190
TEVA NORTH AMERICA	190
THERAVANCE	191
UNITED THERAPEUTICS	191
VECTURA GROUP PLC (UK)	192
CHAPTER 9 KEY DEVELOPMENTS AND COLLABORATIONS	194
HISTORICAL FACTS	194
COMPANIES: DEVELOPMENTS OR INNOVATIVE PRODUCTS	194
ADAMIS PHARMACEUTICALS	195
MICRODOSE THERAPEUTX	195
THERAVANCE AND GLAXOSMITHKLINE	195
Theravance	196
GlaxoSmithKline	196
MYLAN ANNOUNCES ACQUISITION OF RIGHTS TO NOVEL LAMA RESPIRATORY COMPOUND FROM PFIZER	197
GSK'S INCRUSE	197
BOEHRINGER INGELHEIM (BI)	198
Civitas Therapeutics	199
PULMATRIX	199
MANNKIND'S INHALED INSULIN DRUG, AFREZZA	200
NOVARTIS	201
PEARL THERAPEUTICS	201
BAYER SCHERING PHARMA AG, GERMANY	202
DR. REDDY'S LABORATORIES	203
SUN PHARMA	203
SANDOZ	204
TEVA	205
CHAPTER 10 PATENT ANALYSIS	208
PATENT LANDSCAPE AND EFFECT ON SPENDING	208
<i>TABLE 76 COPD KEY FACTS AND CHALLENGES</i>	209
LATEST NEWS	210
ASTRAZENECA	210
REGULATORY ISSUES	210
NEW PATENT FILINGS	211
COMPETITIVE LANDSCAPE	212
<i>TABLE 77 AREAS FOR DRUG DELIVERY IMPROVEMENTS</i>	212
KEY PATENTS	213
Advair and Patent Issues	213
<i>TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS</i>	213
Proventil HFA	214
KEY FACTS	215
CONCLUSION	215

TOPIC	PAGE NO.
CHAPTER 11 REFERENCES	218

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 COMMONLY USED INHALED DRUGS	11
TABLE 2 KEY FACTS	13
TABLE 3 ADVANTAGES AND DISADVANTAGES OF MDIS	13
TABLE 4 ALTERNATIVE TO CFC MDIS	14
TABLE 5 MDIS PHASE-OUT DATES: UNITED STATES	14
TABLE 6 COMMON DPI DEVICES	15
TABLE 7 DPI: ADVANTAGES AND DISADVANTAGES	16
TABLE 8 ADVANTAGES AND DISADVANTAGES OF NEBULIZERS	17
TABLE 9 INHALER DEVICES AND CHARACTERISTICS	27
TABLE 10 DOSAGE FORMS—INHALERS	27
TABLE 11 METERED DOSE INHALERS	28
TABLE 12 DRY POWDER INHALERS	29
TABLE 13 COMMON COPD INHALERS	29
TABLE 14 ASTHMA AND BIOMARKERS	41
TABLE 15 INHALED STEROIDS (ASTHMA INHALERS)	42
TABLE 16 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT	43
TABLE 17 COPD AND LUNG DAMAGE	48
TABLE 18 COMMON COPD INHALERS ON THE MARKET	52
TABLE 19 COPD DRUGS ON THE MARKET	53
TABLE 20 INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR INHALED DRUGS, 2010 (% MARKET SHARE)	56
TABLE 21 INHALER DEVICES	60
TABLE 22 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION	61
TABLE 23 BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS)	64
TABLE 24 BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS)	64
TABLE 25 LIST OF INHALERS FOR ASTHMA AND COPD WITHOUT CFCS	68
TABLE 26 LIST OF METERED DOSE INHALERS AND INGREDIENTS	69
TABLE 27 THE SEVEN CFC INHALERS	71
TABLE 28 TYPES OF DPI DEVICES	74
TABLE 29 DPIS CURRENTLY ON THE MARKET	74
TABLE 30 TYPES OF DRY POWDER INHALERS (DPI)	76
TABLE 31 NEBULIZERS AND DRUGS	78
TABLE 32 NEBULIZERS: ADVANTAGES AND DISADVANTAGES	80
TABLE 33 VIBRATING MESH NEBULIZERS	81
TABLE 34 THERAPEUTIC AGENTS ADMINISTERED BY INHALATION	87
TABLE 35 SHORT-ACTING BRONCHODILATOR INHALERS	89
TABLE 36 LONG-ACTING BRONCHODILATOR INHALERS	90
TABLE 37 INHALED STEROID MEDICATIONS	90
TABLE 38 COMBINATION INHALERS	91
TABLE 39 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 (\$ MILLIONS)	102
TABLE 40 GLOBAL PHARMACEUTICAL SALES AND FORECAST, THROUGH 2018 (\$ BILLIONS)	106
TABLE 41 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY REGION, THROUGH 2017 (\$ BILLIONS)	108

TABLE HEADING	PAGE NO.
TABLE 42 TOP 20 PHARMACEUTICAL COMPANIES, 2012 (\$ MILLIONS)	110
TABLE 43 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 (\$ MILLIONS)	111
TABLE 44 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET	114
TABLE 45 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)	114
TABLE 46 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)	116
TABLE 47 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)	117
TABLE 48 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2018 (\$ MILLIONS)	118
TABLE 49 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)	120
TABLE 50 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	121
TABLE 51 TOP ASTHMA AND COPD DRUGS	122
TABLE 52 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 (\$ MILLIONS)	122
TABLE 53 LEADING PULMONARY DRUG DELIVERY PLAYERS	123
TABLE 54 PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, THROUGH 2018 (\$ MILLIONS)	124
TABLE 55 WORLDWIDE MARKET FOR TOP INHALED DRUGS: SALES AND FORECAST 2012-2013 (\$ MILLIONS)	126
TABLE 56 UNITED STATES: TOP ASTHMA DRUGS SALES, 2012 AND 2013 (\$ MILLIONS)	127
TABLE 57 MARKET FOR MDI TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)	129
TABLE 58 DPI DEVICES	130
TABLE 59 MARKET FOR DPI TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)	131
TABLE 60 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%)	136
TABLE 61 UNITED STATES: TOP ASTHMA DRUGS PRESCRIPTIONS, 2012 (\$ MILLIONS)	137
TABLE 62 NEW PRODUCTS IN THE RESPIRATORY DRUG MARKET, 2013	141
TABLE 63 ADVAIR SALES AND FORECAST, 2011-2015 (\$ MILLIONS)	142
TABLE 64 GLAXOSMITHKLINE: RESPIRATORY DRUGS PHARMACEUTICALS—THREE MONTHS ENDED JUNE 30, 2013 (\$ MILLIONS)	143
TABLE 65 SKYEPHARMA: PRODUCTS	144
TABLE 66 PARTNER NETWORK	145
TABLE 67 TOP SELLING INHALERS, 2010 (\$ MILLIONS)	147
TABLE 68 TOP SELLING DRUGS, 2010 (\$ MILLIONS/+/- %)	149
TABLE 69 GROWTH AREAS FOR INHALERS	150
TABLE 70 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2018 (\$ MILLIONS)	151
TABLE 71 U.S. RESPIRATORY DEVICE MARKET, THROUGH 2018 (\$ MILLIONS)	152
TABLE 72 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2018 (\$ MILLIONS)	153
TABLE 37 INHALED STEROID MEDICATIONS	165
TABLE 74 COPD PRODUCTS	178
TABLE 75 RANGE OF DRY POWDER INHALER DEVICES	179
TABLE 76 COPD KEY FACTS AND CHALLENGES	209
TABLE 77 AREAS FOR DRUG DELIVERY IMPROVEMENTS	212
TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS	213

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, 2011-2018 (\$ MILLIONS)	7
FIGURE 1 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 (\$ MILLIONS)	103
FIGURE 2 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 (\$ BILLIONS)	106
FIGURE 3 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)	115
FIGURE 4 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)	116
FIGURE 5 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 (\$ MILLIONS)	117
FIGURE 6 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018 (\$ MILLIONS)	118
FIGURE 7 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)	120
FIGURE 8 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)	121
FIGURE 9 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 (\$ MILLIONS)	122
FIGURE 10 PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, 2011-2018 (\$ MILLIONS)	124
FIGURE 11 MARKET FOR MDI TECHNOLOGIES, 2011-2018 (\$ MILLIONS)	129
FIGURE 12 MARKET FOR DPI TECHNOLOGIES, 2011-2018 (\$ MILLIONS)	131
FIGURE 13 GLOBAL RESPIRATORY DEVICE MARKET, 2011-2018 (\$ MILLIONS)	151
FIGURE 14 U.S. RESPIRATORY DEVICES MARKET, 2011-2018 (\$ MILLIONS)	153
FIGURE 15 GLOBAL MARKET FOR NEBULIZERS, 2011-2018 (\$ MILLIONS)	154